Table 1.
Demographic, geographical, clinical, and laboratory features of patients with Miller Fisher syndrome (MFS)
| Number (%) | |
|---|---|
| Number of patients | 7 |
| Age: years, median (IQR) (range) | 55, 51 (36–74) |
| Gender: males:females | 4 (57.1):3 (42.9) |
| Country | |
| Spain | 3 (42.9) |
| Italy | 1 |
| UK | 1 |
| New York | 1 |
| Germany | 1 |
| Diagnosis of SARS-CoV-2 infection | |
| Nasopharyngeal swab positive | 6 (85.7) |
| Serology positive | 1 (14.3) |
| Presenting symptoms of COVID-19 | |
| Fever | 5 (71.4%) |
| Cough | 3 (42.9%) |
| Headache | 1 (14.3) |
| Bilateral pneumonia | 1 (14.3) |
| Taste alteration | 1 (14.3) |
| Chills | 1 (14.3) |
| Myalgia | 1 (14.3) |
| Heavy night sweat | 1 (14.3) |
| Weight loss | 1 (14.3) |
| Diarrhea | 1 (14.3) |
| Relationship between onset of COVID-19 and MFS symptoms | |
| Not reported | 3 |
| MFS as presenting feature | 2 |
| Time interval between onset of COVID-19 and MFS in 4 patients: days, median (IQR) (range) | 14.75, 15, (5–24) |
| COVID-19 clinically resolved before MFS | 2 |